The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the nexus of science, policy, and cooperative action, uniting varied stakeholders who pursue the shared goal of advancing the worldwide shift toward animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers highlights the organization’s commitment to preserving strategic direction as it navigates an increasingly intricate global landscape, where expectations surrounding ethical research, scientific precision, and regulatory coherence continue to advance.
Leadership continuity and global representation
The 2026 Board leadership unites senior leaders from the cosmetics, consumer goods, and regulatory advocacy fields, capturing the multi-stakeholder character that has shaped ICCS from the start. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been chosen again to serve as Chair of the Board of Directors. His renewed appointment reflects sustained trust in a leadership style grounded in scientific rigor, international collaboration, and productive dialogue with regulatory authorities.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Acting collectively, the officers form a Board leadership team whose broad background spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than a champion of any specific industry. This balance supports the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Driving progress in animal-free science through collective collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment methods, when rigorously designed and validated, are not only ethically favorable but also scientifically stronger. Since its establishment in early 2023, ICCS has sought to show that non-animal approaches can deliver dependable, relevant insights to safeguard both human well-being and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing involvement from regulators worldwide.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific base and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to offer clearer direction and greater uniformity in applying animal-free safety assessment methods. The guidance sought to connect scientific advances with regulatory needs, delivering a practical framework that stakeholders could use when generating or reviewing non‑animal evidence.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
ICCS has also placed strong emphasis on maintaining ongoing dialogue. Throughout 2025, the organization engaged in wide-ranging interactions with regulators, scientists, and policymakers across multiple regions, guiding discussions on how animal‑free data might be assessed and integrated into existing regulatory frameworks. These exchanges have been essential in building shared understanding and trust, particularly in areas where the incorporation of non‑animal methodologies is still progressing.
A pivotal milestone reshaping the oversight of cosmetics safety
The selection of the 2026 Board officers unfolds amid a period of major shifts in global cosmetics regulation, as numerous markets revisit long‑standing testing mandates in response to evolving public expectations, scientific progress, and broader international policy developments. Within this landscape, organizations such as ICCS hold an essential role by helping bridge innovation and regulatory demands, ensuring that advancement remains both trustworthy and sustainable.
ICCS leadership has consistently emphasized that progress in animal-free safety science cannot arise from isolated efforts; instead, it requires coordinated action among industry, academia, regulators, and civil society. This perspective is reflected in the composition of the Board, which brings together leaders who understand the technical, regulatory, and organizational dimensions necessary to foster significant transformation.
Statements from ICCS leadership after the elections expressed both assurance and realism, highlighting the advances made in recent years while acknowledging that significant hurdles remain. They noted that securing broad regulatory approval for animal-free methods will continue to require ongoing research funding, transparent data exchange, and steady cooperation with authorities to respond to legitimate questions about reliability, practical applicability, and the protection of public health.
The re-elected Chair emphasized the vital need to rely on ICCS’ global, multi-stakeholder framework to close the gap between innovation and regulation, ensuring that advances in animal-free science extend beyond the laboratory and evolve into dependable, consistently implemented tools that regulators can trust.
Strengthening the foundation for enduring influence
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education remains a core element of ICCS’ strategy, as the organization works to provide accessible, science‑based resources and forums for discussion that illuminate the foundations of animal‑free safety science and enable well‑informed decision‑making. This mission becomes particularly crucial in a field where misconceptions or uneven expertise may slow progress, even when the underlying science is strong.
The organization’s structure, encompassing leading cosmetics and ingredient producers alongside trade and research groups as well as animal protection organizations, places it in a distinctive position to tackle these challenges. This broad range of viewpoints helps keep discussions balanced, well‑rooted, and oriented toward common objectives rather than limited agendas.
Based in New York, ICCS continues to operate as a global initiative, highlighting the international scope of cosmetic innovation and regulatory supervision. As products and their components move across borders, harmonized guidelines and mutual recognition of safety protocols become increasingly vital. Through collaborative efforts, ICCS seeks to encourage this coherence, reduce duplicated work, and reinforce trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores stability while hinting at ongoing advancement, with its leadership team providing steady direction after a year marked by concrete achievements and the seasoned perspective needed to guide the next stage of transformation; as scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a unifying hub and driving force for animal-free cosmetics safety science is set to become even more influential.
Ultimately, the importance of the 2026 Board elections rests not only on who is selected, but also on what their leadership conveys: a continued dedication to cooperation, scientific rigor, and the ethical progress of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn ambition into enduring results, guiding the evolution of cosmetics safety in a manner that brings ethics, scientific excellence, and global public confidence into alignment.
